Access cutting-edge endometrial cancer treatment through this clinical trial at a research site in Berkeley. Study-provided care at no cost to qualified participants.
Access endometrial cancer specialists in Berkeley at no cost
This study follows strict safety protocols and ethical guidelines
All study-related endometrial cancer treatment provided free
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this endometrial cancer clinical trial in Berkeley, CA
If you're searching for endometrial cancer treatment options in Berkeley, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Berkeley research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.